Posted on Leave a comment

Non-Invasive Microcirculatory Device Could Help COVID-19 Patients With Underlying Medical Conditions

covid 19

Read article in PRWeb

According to the CDC, nearly 90% of Americans being hospitalized with COVID-19 have an underlying medical condition. Healthcare technology company Circularity Healthcare, creators of D’OXYVA®, is looking to help these patients treat those conditions faster to better their chances of recovery. D’OXYVA® (deoxyhemoglobin vasodilator), the first biotech solution of its kind, provides non-invasive, transdermal microcirculation to improve overall oxygen-rich blood flow – an effective treatment option for a variety of conditions including diabetes, hypertension, cardiovascular issues, COPD, and high blood pressure.

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

“D’OXYVA is aimed at helping millions of people improve their health and their immune response,” says Circularity Healthcare CEO Norbert Kiss. “We are confident this device can save lives in the fight against the Coronavirus by helping repair the body’s functions in people with underlying conditions.” D’OXYVA speeds up the body’s healing process by improving micro and macro circulation and the autonomic nervous system (ANS), detoxifying the liver and kidney, reducing inflammation, and increasing oxygenation and delivery of nutrients. It is the only clinically-tested, non-invasive, portable, transdermal microcirculatory regenerative solution device.

The over-the-counter product is intended to ease the expense and inconvenience of time-consuming doctor visits by offering affordable and effective management of conditions that can take place in the comfort of your own home. “This is truly the future of optimized healthcare,” says Kiss. “D’OXVYA provides an advanced technology that offers a painless solution to help people manage chronic health conditions and see measurable results within a matter of weeks. This is a great way to save time and money by reducing the reliance on opioids and other expensive medications and office visits.”

Extensive clinical research conducted over an eight-year period has already shown incredible success rates. Trials have included over three dozen human clinical studies including double-blind, randomized, and placebo-controlled studies at Pennsylvania State University. The company is now significantly expanding Phase 3 human clinical trials working with the top ten universities in the U.S. targeting underlying conditions specific to COVID-19 risk factors such as oxygen-rich microcirculation in lungs, the heart, kidneys and other vital organs as well as inflammatory markers.

The science used to create the device received a 2019 Nobel Prize in Physiology Medicine. D’OXYVA works by utilizing FDA-cleared, non-toxic molecules (over-the-skin deoxyhemoglobin vasodilator) that deliver a vapor of pharmaceutical-grade CO2 and water to the peripheral microcirculation. This vapor is delivered through the placement of the D’OXYVA device over the thumb for a 5-minute period. The CO2 then travels into the microcirculation of the skin, where it causes a vasodilation that leads to increased perfusion. Since its introduction in 2012, the physician-recommended, easy-to-use device has helped users track and regain their health by repairing or growing new vessels and significantly improving nerve activities in the body.

“The fact is that D’OXYVA increases the effectiveness of the Microcirculatory System,” says Dr. Jim Bledsoe, PHD and Holistic Practitioner. “Increasing the blood flow will help the body improve itself.”

D’OXYVA is currently available OTC online.

The company is actively accepting donation requests from nurses and doctors to provide D’OXYVA for immediate lifesaving treatment of hospital patients in critical condition due to its Investigational Device Exemption (IDE) status under FDA regulations. For more information, please visit doxyva.com/covid-19 or call 626.817.6698.

About Circularity Healthcare, LLC Circularity Healthcare, LLC, located in Los Angeles, CA, is a private biotech and MedTech products and services company that designs, makes, markets, sells, distributes, and licenses its patented and patent-pending technologies, such as its flagship non-invasive deoxyhemoglobin vasodilator product line, D’OXYVA®. One of the main mechanisms underlying D’OXYVA’s science received the Nobel Prize for Medicine in 2019. Circularity enters into exclusive agreements with manufacturers to launch products in large and small clinics and hospitals to help enhance their profits and credit profiles with a wide variety of advanced products and services. In addition, Circularity Healthcare assists in the financing of equipment, working capital, and patient financing at industry-leading terms and speed. For more information, please visit http://www.circularityhealthcare.com or http://doxyva.com; doctors (Rx only) visit http://wound.doxyva.com and send your general inquiries via the Contact Us page. For specific inquiries, contact Circularity Customer Care at info(at)doxyva(dot)com, info(at)Circularity Healthcare(dot)com, or by phone (toll free) at 1-855-5DOXYVA or 1-626-240-0956. Forward-Looking Information This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.